Evidence map›Paper›PMID 38255234›Full record

ArticleBiomedicines2024

Next-Generation Proteomics of Brain Extracellular Vesicles in Schizophrenia Provide New Clues on the Altered Molecular Connectome.

Cristina Lorca, María Fernández-Rhodes, Jose Antonio Sánchez Milán, María Mulet, Félix Elortza, Alfredo Ramos-Miguel, Luis F Callado, J Javier Meana, Maria Mur, Iolanda Batalla and 3 more

Open access · goldAbstract read
In one paragraph

Article in Biomedicines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Cristina LorcaBiomedical Research Institute of Lleida Dr. Pifarré Foundation (IRBLLEIDA), Neuroscience Area, +Pec Proteomics Research Group (+PPRG), University Hospital Arnau de Vilanova (HUAV), 80 Av. Rovira Roure, 25198 Lleida, Spain.ORCID 0000-0002-7975-3691
María Fernández-RhodesBiomedical Research Institute of Lleida Dr. Pifarré Foundation (IRBLLEIDA), Neuroscience Area, +Pec Proteomics Research Group (+PPRG), University Hospital Arnau de Vilanova (HUAV), 80 Av. Rovira Roure, 25198 Lleida, Spain.
Jose Antonio Sánchez MilánBiomedical Research Institute of Lleida Dr. Pifarré Foundation (IRBLLEIDA), Neuroscience Area, +Pec Proteomics Research Group (+PPRG), University Hospital Arnau de Vilanova (HUAV), 80 Av. Rovira Roure, 25198 Lleida, Spain.
María MuletBiomedical Research Institute of Lleida Dr. Pifarré Foundation (IRBLLEIDA), Neuroscience Area, +Pec Proteomics Research Group (+PPRG), University Hospital Arnau de Vilanova (HUAV), 80 Av. Rovira Roure, 25198 Lleida, Spain.
Félix ElortzaProteomics Platform, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), CIBERehd, Science and Technology Park of Bizkaia, 48160 Derio, Spain.ORCID 0000-0001-8839-5438
Alfredo Ramos-MiguelDepartment of Pharmacology, University of the Basque Country UPV/EHU, 48940 Leioa, Spain.ORCID 0000-0001-6259-1836
Luis F CalladoDepartment of Pharmacology, University of the Basque Country UPV/EHU, 48940 Leioa, Spain.ORCID 0000-0001-9941-012X
J Javier MeanaDepartment of Pharmacology, University of the Basque Country UPV/EHU, 48940 Leioa, Spain.ORCID 0000-0002-7913-6714
Maria MurPsychiatry Department, Hospital Universitari Santa Maria, Medicine Department, Universitat de Lleida (UdL), 25198 Lleida, Spain.
Iolanda BatallaPsychiatry Department, Hospital Universitari Santa Maria, Medicine Department, Universitat de Lleida (UdL), 25198 Lleida, Spain.ORCID 0000-0003-2652-8463
Elisabet VilellaCentro de Investigación Biomédica en Red en Salud Mental CIBERSAM, Instituto de Salud Carlos III, 43206 Reus, Spain.ORCID 0000-0002-1887-5919
Aida SerraDepartment of Medical Basic Sciences, Biomedical Research Institute of Lleida Dr. Pifarré Foundation (IRBLLEIDA), +Pec Proteomics Research Group (+PPRG), University of Lleida (UdL), 25198 Lleida, Spain.
Xavier Gallart-PalauBiomedical Research Institute of Lleida Dr. Pifarré Foundation (IRBLLEIDA), Neuroscience Area, +Pec Proteomics Research Group (+PPRG), University Hospital Arnau de Vilanova (HUAV), 80 Av. Rovira Roure, 25198 Lleida, Spain.
Universitat de Lleida · ESUniversity of the Basque Country · ESCIC bioGUNE · ESInstituto de Salud Carlos III · ES

Funding

Agencia Estatal de Investigación PID2020-114885RB-C21Agency for Administration of University and Research AGAUR 21SGR010065Basque Government IT1512/22Basque Government IT211/19Diputació de Lleida PIRS22/03Diputació de Lleida PIRS23/02Government of Catalonia EVBRAINTARGET-Y7340-ACPPCCOL007Instituto de Salud Carlos III PI22/00443Ministerio de Ciencia e Innovación PRTR-C17.I1
6 · The paper itself

Abstract

Extracellular vesicles (EVs) are tiny membranous structures that mediate intercellular communication. The role(s) of these vesicles have been widely investigated in the context of neurological diseases; however, their potential implications in the neuropathology subjacent to human psychiatric disorders remain mostly unknown. Here, by using next-generation discovery-driven proteomics, we investigate the potential role(s) of brain EVs (bEVs) in schizophrenia (SZ) by analyzing these vesicles from the three post-mortem anatomical brain regions: the prefrontal cortex (PFC), hippocampus (HC), and caudate (CAU). The results obtained indicate that bEVs from SZ-affected brains contain region-specific proteins that are associated with abnormal GABAergic and glutamatergic transmission. Similarly, these vesicles from the analyzed regions were implicated in synaptic decay, abnormal brain immunity, neuron structural imbalances, and impaired cell homeostasis. Our findings also provide evidence, for the first time, that networks of molecular exchange (involving the PFC, HC, and CAU) are potentially active and mediated by EVs in non-diseased brains. Additionally, these bEV-mediated networks seem to have become partially reversed and largely disrupted in the brains of subjects affected by SZ. Taken as a whole, these results open the door to the uncovering of new biological markers and therapeutic targets, based on the compositions of bEVs, for the benefit of patients affected by SZ and related psychotic disorders.

Indexed as

brain antibodiesextracellular vesiclesimmunoglobulinsmolecular exchangeneuroinflammationpsychiatrypsychotic spectrumsystems biology

Identifiers

PMID38255234
PMCPMC10812948
OpenAlexW4390780055

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.